ghostwriting news from FiercePharma
News
Merck swears off ghostwriting in settlement
Merck made a $58 million deal to settle claims of deceptive Vioxx advertising with a 29 attorneys general. The states had alleged that Merck deceived consumers by concealing the "increased risks" Read more...
JAMA thumbs-down for off-label proposal
Considering the ghostwriting scandal it touched off last week, it's not surprising that the Read more...
Ghostwriting fuels foes of FDA rule change
Last week, we reported on Big Pharma's march on the capital in support of new off-label marketing rules. Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets